rosiglitazone maleate

Phase 3Small molecule

GSK

rosiglitazone maleate is one of 134 small molecule programs targeting Oral leukoplakia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral LeukoplakiaActive, not recruiting

AtherosclerosisActive, not recruiting

Pituitary TumorActive, not recruiting

LiposarcomaActive, not recruiting

Thyroid CancerActive, not recruiting

Type 2 DiabetesActive, not recruiting

Oral LeukoplakiaPhase 2

Active, not recruiting

AtherosclerosisPhase 3

Active, not recruiting

Pituitary TumorPhase 2

Active, not recruiting

LiposarcomaPhase 2

Active, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

rosiglitazone maleate

GSK

Phase 3

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 10

Forxiga

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pituitary Tumor2 trials

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00612066·2 enrolled

Rosiglitazone in Treating Patients With Pituitary Tumors

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00616642·1 enrolled

Cystectomy1 trial

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Withdrawn·FFox Chase Cancer Center·N/A·NCT00084578

Thyroid Cancer1 trial

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Unknown status·UUniversity of California, San Francisco·Phase 2·NCT00098852·25 enrolled

Oral leukoplakia1 trial

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00369174·25 enrolled

Interaction1 trial

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00362726·14 enrolled

6 more indications

Metformin1 trial

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00015691·105 enrolled

Treatment1 trial

Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels

Completed·UUniversity of British Columbia·N/A·NCT00143624·50 enrolled

Type 2 Diabetes1 trial

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00484419·169 enrolled

Atherosclerosis1 trial

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Completed· GSK logo

GSK·Phase 3·NCT00116831·672 enrolled

Biomarkers1 trial

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

Completed· GSK logo

GSK·Phase 1·NCT00551564·36 enrolled

Liposarcoma1 trial

Rosiglitazone in Treating Patients With Liposarcoma

Completed·—·Phase 2·NCT00004180·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for rosiglitazone maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rosiglitazone maleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rosiglitazone maleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

rosiglitazone maleate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pituitary Tumor2 trials

Cystectomy1 trial

Thyroid Cancer1 trial

Oral leukoplakia1 trial

Interaction1 trial

Metformin1 trial

Treatment1 trial

Type 2 Diabetes1 trial

Atherosclerosis1 trial

Biomarkers1 trial

Liposarcoma1 trial

References

Drug Info

Quick Facts

Related News